Phase I Study of Erlotinib (Tarceva) in Combination With AT-101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 13 May 2015
At a glance
- Drugs AT 101; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 25 Jun 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 01 Jan 2010 Planned initiation date (Feb 2010) added as reported by ClinicalTrials.gov.
- 01 Jan 2010 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.